ArticleCurrent microbiology2026
Untargeted Metabolomics and Bioactivity Screening of Mycelial Culture Extracts from Marasmioid Fungi.
Article in Current microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Basidiomycota is a cosmopolitan fungal phylum recognized for its nutritional properties and as a natural source of bioactive compounds. Within this group, the family Marasmiaceae Roze ex Kühner remains comparatively understudied. In this study, we performed a metabolic characterization and bioactivity screening of four marasmioid fungal strains using untargeted metabolomic and bioinformatic tools to analyze the metabolic profiles of broth extracts from strains Montiel04, FGR1289, FGR1276, and CC45, detecting 296, 447, 167, and 99 spectrometric features (m/z_RT), respectively. The extracts exhibited notable antibacterial activity, particularly against Clavibacter michiganensis and Erwinia persicina, with strain FGR1289 demonstrating the highest efficacy. Furthermore, extracts from strains FGR1289 and FGR1276 exhibited significant antioxidant capacity against ABTS
Indexed as
Identifiers
42627539What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.